Literature DB >> 24084080

Differential IRAK signaling in hematologic malignancies.

Garrett W Rhyasen1, Lyndsey Bolanos, Daniel T Starczynowski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24084080      PMCID： PMC4665116          DOI： 10.1016/j.exphem.2013.09.008

Source DB:  PubMed          Journal:  Exp Hematol        ISSN： 0301-472X            Impact factor:   3.084


× No keyword cloud information.
  10 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 2.  Myelodysplastic syndromes: the complexity of stem-cell diseases.

Authors:  Seth J Corey; Mark D Minden; Dwayne L Barber; Hagop Kantarjian; Jean C Y Wang; Aaron D Schimmer
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 3.  The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling.

Authors:  Sinead Flannery; Andrew G Bowie
Journal:  Biochem Pharmacol       Date:  2010-06-23       Impact factor: 5.858

Review 4.  Functional diversity and regulation of different interleukin-1 receptor-associated kinase (IRAK) family members.

Authors:  Sophie Janssens; Rudi Beyaert
Journal:  Mol Cell       Date:  2003-02       Impact factor: 17.970

5.  MyD88, an adapter protein involved in interleukin-1 signaling.

Authors:  K Burns; F Martinon; C Esslinger; H Pahl; P Schneider; J L Bodmer; F Di Marco; L French; J Tschopp
Journal:  J Biol Chem       Date:  1998-05-15       Impact factor: 5.157

6.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.

Authors:  A Pellagatti; M Cazzola; A Giagounidis; J Perry; L Malcovati; M G Della Porta; M Jädersten; S Killick; A Verma; C J Norbury; E Hellström-Lindberg; J S Wainscoat; J Boultwood
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

7.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

8.  IRAK: a kinase associated with the interleukin-1 receptor.

Authors:  Z Cao; W J Henzel; X Gao
Journal:  Science       Date:  1996-02-23       Impact factor: 47.728

9.  Toll-like receptor alterations in myelodysplastic syndrome.

Authors:  Y Wei; S Dimicoli; C Bueso-Ramos; R Chen; H Yang; D Neuberg; S Pierce; Y Jia; H Zheng; H Wang; X Wang; M Nguyen; S A Wang; B Ebert; R Bejar; R Levine; O Abdel-Wahab; M Kleppe; I Ganan-Gomez; H Kantarjian; G Garcia-Manero
Journal:  Leukemia       Date:  2013-06-14       Impact factor: 11.528

10.  Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome.

Authors:  Garrett W Rhyasen; Lyndsey Bolanos; Jing Fang; Andres Jerez; Mark Wunderlich; Carmela Rigolino; Lesley Mathews; Marc Ferrer; Noel Southall; Rajarshi Guha; Jonathan Keller; Craig Thomas; Levi J Beverly; Agostino Cortelezzi; Esther N Oliva; Maria Cuzzola; Jaroslaw P Maciejewski; James C Mulloy; Daniel T Starczynowski
Journal:  Cancer Cell       Date:  2013-07-08       Impact factor: 31.743
  10 in total
  10 in total

Review 1.  The inflammatory microenvironment in MDS.

Authors:  Lili Yang; Yaqin Qian; Erika Eksioglu; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Cell Mol Life Sci       Date:  2015-02-08       Impact factor: 9.261

Review 2.  Deconstructing innate immune signaling in myelodysplastic syndromes.

Authors:  Madeline Niederkorn; Molly Smith; Laura Barreyro; Melinda E Varney; Katelyn Melgar; Daniel T Starczynowski
Journal:  Exp Hematol       Date:  2015-07-02       Impact factor: 3.084

Review 3.  Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.

Authors:  I Gañán-Gómez; Y Wei; D T Starczynowski; S Colla; H Yang; M Cabrero-Calvo; Z S Bohannan; A Verma; U Steidl; G Garcia-Manero
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

4.  Targeting IRAK1 in T-cell acute lymphoblastic leukemia.

Authors:  Charles Dussiau; Amélie Trinquand; Ludovic Lhermitte; Mehdi Latiri; Mathieu Simonin; Agata Cieslak; Nawel Bedjaoui; Patrick Villarèse; Els Verhoeyen; Hervé Dombret; Norbert Ifrah; Elizabeth Macintyre; Vahid Asnafi
Journal:  Oncotarget       Date:  2015-08-07

5.  Pelle Modulates dFoxO-Mediated Cell Death in Drosophila.

Authors:  Chenxi Wu; Yujun Chen; Feng Wang; Changyan Chen; Shiping Zhang; Chaojie Li; Wenzhe Li; Shian Wu; Lei Xue
Journal:  PLoS Genet       Date:  2015-10-16       Impact factor: 5.917

Review 6.  NF-κB: A Druggable Target in Acute Myeloid Leukemia.

Authors:  Barbara Di Francesco; Daniela Verzella; Daria Capece; Davide Vecchiotti; Mauro Di Vito Nolfi; Irene Flati; Jessica Cornice; Monica Di Padova; Adriano Angelucci; Edoardo Alesse; Francesca Zazzeroni
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

7.  Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.

Authors:  Mona M Hosseini; Stephen E Kurtz; Sherif Abdelhamed; Shawn Mahmood; Monika A Davare; Andy Kaempf; Johannes Elferich; Jason E McDermott; Tao Liu; Samuel H Payne; Ujwal Shinde; Karin D Rodland; Motomi Mori; Brian J Druker; Jack W Singer; Anupriya Agarwal
Journal:  Leukemia       Date:  2018-03-29       Impact factor: 11.528

Review 8.  Toll-like receptor signaling in hematopoietic homeostasis and the pathogenesis of hematologic diseases.

Authors:  Joseph Cannova; Peter Breslin S J; Jiwang Zhang
Journal:  Front Med       Date:  2015-08-22       Impact factor: 4.592

9.  IRAK1: oncotarget in MDS and AML.

Authors:  Levil J Beverly; Daniel T Starczynowski
Journal:  Oncotarget       Date:  2014-04-15

10.  Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.

Authors:  Melinda E Varney; Madeline Niederkorn; Hiroyasu Konno; Takayuki Matsumura; Jin Gohda; Nobuaki Yoshida; Taishin Akiyama; Susanne Christie; Jing Fang; David Miller; Andres Jerez; Aly Karsan; Jaroslaw P Maciejewski; Ruhikanta A Meetei; Jun-ichiro Inoue; Daniel T Starczynowski
Journal:  J Exp Med       Date:  2015-10-12       Impact factor: 14.307
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.